Economy/Home · Economy

[Breaking] Kolon TissueGene Surges During Trading... Recovers 24,000 Level Despite VI Activation, Aims for 5th Consecutive Day of Gains

Kolon TissueGene (950160) surged in early trading on the 13th, recovering the 24,000 won level for the first time in about three months. As of 9:43 a.m. on this day, Kolon TissueGene is trading at 24,350 won, up 3,000 won (14.05%) from the previous trading day. This marks the first time the stock h

Oseong Kwon
Staff Reporter
3 min read
[Breaking] Kolon TissueGene Surges During Trading... Recovers 24,000 Level Despite VI Activation, Aims for 5th Consecutive Day of Gains
CBC News

Kolon TissueGene (950160) surged in early trading on the 13th, recovering the 24,000 won level for the first time in about three months.

As of 9:43 a.m. on this day, Kolon TissueGene is trading at 24,350 won, up 3,000 won (14.05%) from the previous trading day. This marks the first time the stock has surpassed the 24,000 won level since July 22.

Earlier, at 9:35:47 a.m. on the same day, the Static Volatility Interruption (VI) was activated and then lifted at 9:37:48 a.m. Even after the VI was lifted, the upward momentum remained unbroken, with the stock hovering above the 24,000 won level.

■ Aiming for a 5th consecutive trading day of gains following 4 consecutive days of increases

Looking at recent closing prices, Kolon TissueGene started at 17,660 won on the 7th and rose for four consecutive trading days, reaching 19,330 won on the 10th, 19,620 won on the 11th, and 21,350 won on the 12th. Including today's intraday strength, this marks five consecutive trading days of upward momentum.

The stock also recovered the 20,000 won level during trading the previous day with a VI activation, indicating that recent price volatility has clearly widened.

Whether Kolon TissueGene, which recorded a double-digit gain on this day, will close with a fifth consecutive trading day of strength and whether it will hold the 24,000 won level until the end remains the market's focus.

[This article is by no means an investment recommendation. All investments are made at the individual's own discretion, and the final responsibility lies with the investor.]

Oseong Kwon
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.